January 05, 2022
Article
Agency greenlights secukinumab’s use for pediatric Treatment of enthesitis-related arthritis and Juvenile psoriatic arthritis.
December 17, 2021
Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.
December 15, 2021
The safety profile observed in patients with active psoriatic arthritis administered upadacitinib was consistent with the safety profile observed in patients with rheumatoid arthritis.
October 27, 2021
Apremilast is indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet disease.
August 20, 2021
The investigators concluded that a definite statement on risk or management recommendations cannot be made based on currently published data.
June 10, 2021
Risankizumab-rzaa (Skyrizi, AbbVie) is approved for the treatment of moderate-to-severe plaque psoriasis among adults who are candidates for systemic therapy or phototherapy.
June 07, 2021
Guselkumab also showed promising results in the treatment of psoriatic arthritis, with improved disease activity in joints and across multiple domains through 1 year.
June 03, 2021
This is the first approval for secukinumab in a pediatric population in the United States for severe plaque psoriasis.
April 23, 2021
The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.
April 06, 2021
Some drugs commonly used for psoriasis can increase the risk of cardiovascular diseases, whereas other treatments can reduce the risk.
